Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAMOND: Dulaglutide and insulin microsecretion in type 1 diabetes
2018-000393-29Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Dulaglutide + insulin with Placebo + insulin (2 arms). Primary endpoint: HbA1c at 24 weeks. Started Apr 2018; status: completed.
02
Drugs
dulaglutide
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2018-000393-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000393-29.